Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Cronos Group Can't Hold a Candle to Aurora Cannabis or Canopy Growth

By Sean Williams - Apr 4, 2019 at 7:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cronos is the new third-largest pot stock, but it has no business being listed side by side with its larger peers.

In case you missed it, something interesting happened in the marijuana industry over the past couple of weeks. Namely, Cronos Group ( CRON -5.46% ) surpassed Tilray ( TLRY ) to become the third-largest publicly traded pot stock in the world behind only Canopy Growth ( CGC -3.57% ) and Aurora Cannabis ( ACB -5.21% ).

Why Cronos Group leaped over Tilray into the No. 3 spot

The lift for Cronos Group came from the closing of the $1.8 billion equity investment into the company by Altria ( MO 1.64% ). Upon closing, Altria took a nondiluted 45% stake in Cronos, with the potential to up its ownership to 55% if it chooses to execute warrants that were received as part of the investment. Considering the precipitous decline in tobacco shipment volumes that Altria has been contending with in the U.S., this investment gives the U.S. tobacco king access to a rapidly growing trend (i.e., cannabis) in North America.

An up-close view of flowering cannabis plants.

Image source: Getty Images.

Meanwhile, the $1.8 billion cash infusion from Altria vaulted Cronos to the No. 2 spot in terms of cash on hand among pot stocks, behind only Canopy Growth. The company ended the previous quarter with less than $25 million in cash on hand, so the $1.8 billion now gives it the freedom to execute on its long-term strategy.

Meanwhile, around the same time as Cronos Group closed on its equity investment from Altria, Tilray reported its fourth-quarter results. The $15.5 million in sales, the 20% gross margin, and the $0.33 per share loss were all less-than-desirable outcomes after Canada had legalized recreational marijuana this past October. Plus, with Tilray CEO Brendan Kennedy announcing that the company would focus its efforts on the U.S. and Europe, essentially throwing in the towel on future investments in Canada, it looks as if Tilray is a rudderless ship adrift at sea for the time being.

Add this up, and it's pretty easy to see how Cronos Group usurped the No. 3 market-cap spot from Tilray. But let's make one thing very clear: Cronos Group can't hold a candle to Aurora Cannabis or Canopy Growth.

A person holding a magnifying glass over a potted cannabis plant.

Image source: Getty Images.

Canopy and Aurora could run circles around Cronos 

Even though Cronos now finds itself in elite company among marijuana stocks, it has very little going for it beyond its Altria equity investment. Aside from this cash and Cronos Group's up to $100 million deal with Ginkgo Bioworks to develop cannabinoids at commercial scale, the company has absolutely no business being listed anywhere near Canopy or Aurora.

On the basis of production, Aurora Cannabis is liable to lead all growers with around 700,000 kilos in peak yield by 2021 or 2022. Canopy Growth, while more tight-lipped about its peak yearly output, does have more than 4.3 million square feet of its 5.6 million square feet already licensed by Health Canada. This should put the company on track for (comfortably) more than 500,000 kilos in peak annual production. Meanwhile, Cronos Group would have to scrape every bud together to maybe hit 120,000 kilos a year of output.

Delving deeper into production, Aurora Cannabis has more than a dozen facilities that will help it reach No. 1 production status. Canopy Growth has 10 facilities accounting for its 5.6 million square feet. As for Cronos Group, it has an 850,000-square-foot joint venture capable of 70,000 kilos at its peak; Peace Naturals, which will yield 40,000 kilos at its maximum, and three other marginally producing facilities. In another context, Aurora has three facilities that come close to outproducing Cronos Group -- if not flat-out doing so.

A person holding cannabis leaves in front of a globe of the Earth.

Image source: Getty Images.

Additionally, Aurora Cannabis has pushed into 24 total markets, with Canopy Growth easily surpassing one dozen. These international sales channels are extremely important given the likelihood that dried cannabis flower will eventually be oversupplied and commoditized in Canada. Thus, having a presence in overseas markets will ensure that Aurora and Canopy don't see their domestic operating margins get ransacked by falling per-gram prices for dried flower.

As for Cronos, it has a small production presence in Australia and Israel, as well as distribution platforms in Poland and Germany. But that's about it when it comes to international expansion.

To make this comparison even more night-and-day, Canopy Growth and Aurora Cannabis reported sales of $62.3 million and $40.6 million, respectively, in their most recent quarter. Comparatively, even with recreational legalization, Cronos Group managed only $4.2 million in sales. It was surpassed by numerous growers with significantly smaller market caps.

In sum, yes, Cronos Group is the new No. 3 in market cap among pot stocks. But no, it doesn't remotely deserve to be anywhere near the top of the list. My suggestion is to not become enamored with Cronos Group's recent success and instead avoid what looks to be the most overvalued marijuana stock of them all.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$9.99 (-3.57%) $0.37
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$5.82 (-5.21%) $0.32
Cronos Group Stock Quote
Cronos Group
CRON
$4.16 (-5.46%) $0.24
Altria Group, Inc. Stock Quote
Altria Group, Inc.
MO
$43.92 (1.64%) $0.71
Tilray Stock Quote
Tilray
TLRY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.